Valuation: Waverley Pharma Inc.

Market Cap 540K 377K 343K 316K 288K 34.91M 568K 3.85M 1.53M 19.07M 1.41M 1.38M 59.85M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 3.94M 2.75M 2.51M 2.31M 2.1M 255M 4.14M 28.1M 11.17M 139M 10.32M 10.1M 437M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day-50.00%
1 week-50.00%
3 months-33.33%
Current year-50.00%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.1
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 2020-01-31
Director of Finance/CFO - 2019-12-31
Director TitleAgeSince
Chairman 79 2016-12-13
Director/Board Member 54 2016-12-13
Director/Board Member - 2023-11-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Option

Chairman

-10,000,000 18.5185%
6/24/24 Other

Director

0 0.0000%
8/18/21 Other

Chairman

0 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-50.00%-33.33%-71.43% 377K
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -6.24%-1.09%+26.43%+155.34% 40B
Weighted average by Cap. -1.48%-1.85%+31.83%+155.14%

Financials

2024 2025
Net sales 475K 332K 302K 279K 253K 30.74M 500K 3.39M 1.35M 16.79M 1.25M 1.22M 52.69M 1.35M 942K 858K 791K 719K 87.26M 1.42M 9.63M 3.83M 47.66M 3.54M 3.46M 150M
Net income -947K -661K -602K -555K -505K -61.23M -995K -6.75M -2.68M -33.45M -2.48M -2.43M -105M -499K -349K -317K -293K -266K -32.28M -525K -3.56M -1.42M -17.63M -1.31M -1.28M -55.33M
Net Debt 2.83M 1.98M 1.8M 1.66M 1.51M 183M 2.97M 20.19M 8.02M 99.96M 7.42M 7.26M 314M 3.4M 2.37M 2.16M 1.99M 1.81M 220M 3.57M 24.24M 9.64M 120M 8.91M 8.72M 377M
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock